Replies to post #19497 on Biotech Values

[walldiver]

Yes, it's ironic and sad. The other factor in play here is that patients in either arm are allowed to receive Taxotere or other taxanes during the three-year followup period. For the 9901 trial, patients in the placebo arm received Taxotere at a 33% higher rate than patients in the Provenge arm. The taxane numbers for 9902A have not yet been released. Also, all-cause mortality figures have not yet been released for either trial...perhaps awaiting journal publication.

[DewDiligence]

>Given that there is some indication of Provenge efficacy, it seems to me it would be hard to do a trial now without crossovers allowed. So, ironically, the more effective that Provenge seems to be, the harder it becomes in practice to do a rigorous trial.<

All drug sponsors face this issue to some degree.

It astonishes me that some of the DNDN bulls who post on message boards think that DNDN is entitled to special treatment from the FDA on matters that other sponsors deal with routinely.